Podcasts about biomedical data science

The tasks that AI is able to perform has grown exponentially over the years but there are a few things AI still struggles with, like accurately mimicking scientific methodology. Dr. James Zou joins host Dr. Samantha Yammine today to discuss recent updates in AI's ability to play the role of scientist. He is an associate professor of Biomedical Data Science at Stanford University where he created a research lab of AI scientists. Sam also investigates the ins and outs of lab-grown meat and how MDMA is being used to treat PTSD. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we speak with Dr. Roxana Daneshjou, MD/PhD, a physician-scientist who combines her expertise in dermatology and artificial intelligence.  Dr. Daneshjou shares her journey, which began with studying Bioengineering at Rice University, followed by earning her MD and PhD in Genetics at Stanford School of Medicine. She completed her dermatology residency at Stanford as part of the research track and went on to complete a postdoc in Biomedical Data Science.  In our conversation, Dr. Daneshjou discusses the evolution of AI in dermatology, what the future holds for the field, and offers valuable advice for aspiring dermatologists and physician-scientists. Tune in and enjoy this insightful episode! Connect with Dr.Daneshjou: Linkedin ⁠⁠https://www.linkedin.com/in/roxanadaneshjou/⁠⁠ BlueSky Social: ⁠⁠https://web-cdn.bsky.app/profile/roxanadaneshjou.bsky.social⁠⁠ --- DIGA: @⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠derminterest⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Today's Host: Shan Francis⁠⁠⁠⁠⁠⁠⁠ --- For questions, comments, or future episode suggestions, please reach out to us via email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠derminterestpod@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Music: District Four by Kevin MacLeod Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://incompetech.filmmusic.io/song/3662-district-four⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ License: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://filmmusic.io/sta

Episode 032 | Tofunmi Omiye, MD, MS is an incoming dermatology resident (class of 2028) at Stanford and is currently a postdoctoral scholar at Stanford University where he works in the Daneshjou (shout out Roxana!) and Zaba (shout out Lisa!) Labs that are part of the departments of Dermatology and Biomedical Data Science.Dr. Omiye works at the nexus of artificial intelligence, healthcare, and policy. His research covers computer vision, foundation models, and AI bias. His projects have been published in journals like Nature Medicine and featured in media outlets like the Washington Post and AP news.Before Stanford, Tofunmi earned his medical degree from the University of Ibadan, Nigeria, where he was privileged to be a Federal Govt. and Shell University Scholar. He later pursued an MS in Health Policy at Stanford while focusing on AI and working in a surgery-AI lab. Here, he explored the utility of machine learning algorithms in clinical settings and how macroeconomic policies influence mortality.Dr. Omiye has previously collaborated on global health projects with the WHO and Gates foundation and had a stint in venture capital supporting early stage investments in the San Francisco Bay Area. He is passionate about helping ensure that AI benefits all patients, and enjoys concerts, and the real Football. ⚽️This episode was recorded in June 2024.Connect with and learn more about Dr. Omiye

In this podcast episode, Dr. James Zou, Associate Professor of Biomedical Data Science and Faculty DIrector of the AI for Health department at Stanford University, shares current use cases for AI in healthcare and oncology and discusses how we can overcome challenges with LLMs to unlock the full potential of AI.

Physiological Reviews Editor-in-Chief Dr. Sadis Matalon speaks with    Prof. John P.A. Ioannidis about his editorial “Systematic Reviews for Basic Scientists: A Different Beast,” which focuses on the importance of systematic reviews in scientific research. Prof. Ioannidis is Professor of Medicine, of Epidemiology and Population Health, and, by courtesy, of Statistics and Biomedical Data Science at Stanford University. He is one of the most cited scientists in the world and is an elected member of numerous national academies. Prof. Ioannidis in an Associate Editor of Physiological Reviews. Introduction of Prof. Ioannidis [1:26] Author's background [3:08] Discussion of reproducibility in science [5:35] Discussion of sample size in research [7:31] What exactly is a systematic review, and how can it address bias? [10:41] Do systematic reviews have a place in basic research, or should they be used mostly in clinical science? [13:29] What is a “living review”? [15:35] What does the future hold for the format of review articles? [18:34] The importance of collaboration in science [21:50] Advice for early-career researchers [24:57] Subscribe to the podcast on Apple Podcasts, Google Podcasts, Spotify, and Amazon Music to receive immediate notification when new episodes are available. Browse recent articles on our website. Be sure to let your colleagues know about the podcast, and please rate and review it wherever you listen to it. Follow the journal on Twitter and Facebook. Listen to other podcasts produced by the American Physiological Society.

Carlos Bustamante, over the past 15 years, has led a multidisciplinary team working on problems at the interface of computational and biological sciences. Much of his research has focused on genomics technology and its application in medicine, agriculture, and evolutionary biology. His first academic appointment was at Cornell University's College of Agriculture and Life Sciences. There, much of his work focused on population genetics and agricultural genomics motivated by a desire to improve the foods we eat and the lives of the animals upon which we depend. He moved to Stanford in 2010, to focus on enabling clinical and medical genomics on a global scale. He has been particularly focused on reducing health disparities in genomics by: (1) calling attention to the problem raised by >95% of participants in large-scale studies being of European descent; and (2) broadening representation of understudied groups, particularly U.S. minority populations and those from Latin America. Taken together, this work has empowered decision-makers to utilize genomics and data science in the service of improving human health and wellbeing. As Inaugural Chair of Stanford's new Department of Biomedical Data Science, his future goal is to scale these operations from focusing on researchers to consumers and patients, where we ultimately want our work to have the greatest impact.In 2017, Bustamante was appointed a Chan-Zuckerberg Investigator and, from 2011–2016, he was a MacArthur Fellow. He also received a Stanford Prize in Population Genetics and Society in 2016, a Sloan Research-Fellowship in Molecular Biology from 2007–2009, and a Marshall-Sherfield Fellowship from 2001–2002. Bustamante also has a strong interest in building new academic units, non-profits, and companies. He is Founding Director (with Marcus Feldman) of the Stanford Center for Computational, Evolutionary, and Human Genomics (CEHG), and former Founding Associate Director of the Cornell Center for Comparative and Population Genomics (3CPG).He serves as an advisor to the US federal government, private companies, startups, and non-profits in the areas of computational genomics, population and medical genetics, and veterinary and plant genomics. He is currently Director of EdenRoc Sciences, Founder @ Arc Bio, & an SAB member of: Embark Veterinary, the Mars/IBM Food Safety Board, & Digitalis Ventures.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

In this episode Ellie Murray and Lucy D'Agostino McGowan chat with Enrique Schisterman, Perelman Professor and Chair of the Department of Biostatistics, Epidemiology, and Informatics at the University of Pennsylvania, about the future of epidemiology. Follow along on Twitter: Enrique: @eschisterman1 The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats

Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.

Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.

In Episode 3 of Exploration Science, Trishul Shah, Director of Business Development at PolyPeptide Group, walks through the process of personalized medicine from needle to needle. Jon Collins, Vice President of Business Development at CEM, also joins us to discuss some challenges faced by the field of peptide-based personalized medicine and opportunities for technology to help. Andrea Castro, Maurizio Zanetti, Hannah Carter. Neoantigen Controversies. Annual Review of Biomedical Data Science 2021 4:1, 227-253 https://doi.org/10.1146/annurev-biodatasci-092820-112713 https://www.polypeptide.com/wp-content/uploads/2019/12/NeoAntigen.pdf https://www.polypeptide.com/neoantigen-peptides-napp/

In Episode 3 of Exploration Science, Trishul Shah, Director of Business Development at PolyPeptide Group walks through the process of personalized medicine from needle to needle. Jon Collins, Vice President of Business Development at CEM also joins us to discuss some challenges faced by the field of peptide-based personalized medicine and opportunities for technology to help. Andrea Castro, Maurizio Zanetti, Hannah Carter. Neoantigen Controversies. Annual Review of Biomedical Data Science 2021 4:1, 227-253 https://doi.org/10.1146/annurev-biodatasci-092820-112713 https://www.polypeptide.com/wp-content/uploads/2019/12/NeoAntigen.pdf https://www.polypeptide.com/neoantigen-peptides-napp/

In this episode, the team discusses genetics with Kenneth Fong Professor of Bioengineering, Genetics, Medicine, and Biomedical Data Science, Russ Biagio Altman. Follow Russ on Twitter @RBAltman. Make sure to listen to “The Future of Everything" on Channel 121 On SiriusXM, Apple Podcasts, Spotify, or wherever you listen to podcasts. Go to LoopedLive.com to buy tickets to our live virtual event! Find it under upcoming experiences! Go to JimJefferies.com to buy tickets to Jim's upcoming tour, The Moist Tour. See omnystudio.com/listener for privacy information.

Welcome back to Season 3 of the Not Mini Adults Podcast.  To kick off Season 3 we have a very special guest and spend our time talking about the importance of data and AI and what it will mean for our children's wellbeing now and in the future.  This week we are talking to Dr. Anthony Chang.  Dr. Chang is the Chief Intelligence and Innovation Officer as well as Medical Director of the Heart Failure Program at Children's Hospital of Orange County.  Dr Chang also founded the Medical Intelligence and Innovation Institute (MI3) at CHOC Children's. Dr. Chang holds an MD from Georgetown, an MPH from UCLA, an MBA from the University of Miami, holds a certification from MIT on AI, and has an MS in Biomedical Data Science from Stanford.Anthony has been called “Dr. AI” by the Chicago Tribune having published numerous peer reviewed papers in ML and AI related to medicine.  He is passionate about how AI can transform healthcare and works tirelessly in advancing the use of AI.  Dr Chang is also one of the original founders of the International Society for Paediatric Innovation and to us is the Godfather of Paediatric Innovation. Visit our shop here to purchase a copy of the Thinking of Oscar Cookbook - Made with Love or Face Coverings. THANK YOU! Thinking of Oscar website and contact details can be found here. Follow us on Twitter here or Instagram here. Theme Music - ‘Mountain' – copyright Lisa Fitzgibbon 2000 Written & performed by Lisa Fitzgibbon, Violin Jane Griffiths Podcast artwork thanks to The Podcast Design Experts

On the path from scientific discovery to new drug, the clinical trial is a huge — and critical — hurdle. Clinical trials are themselves experiments, and to make sure that they are doing the best possible job at determining the safety and efficacy of the new drug, we need to be able to do experiments on those experiments. But how do you do that in such a highly regulated space? Host Lauren Richardson talks to James Zou, Assistant Professor of Biomedical Data Science at Stanford University, and a16z general partner Vineeta Agarwala, physician and expert on real world data in healthcare, about new research from the Zou lab that uses AI-powered simulations of clinical trials and real world patient data to understand how different designs influence trial outcomes. In particular, looking for designs that can make trials more inclusive, which is key for getting patients access to potentially life-saving care and for running trials efficiently. The conversation covers the inherited rules and assumptions governing which patients can participate in trials, how Dr. Zou, lead author Ruishan Liu, and colleagues combined real world data and computer simulations to challenge these assumptions via a data-driven approach, and how this can inform smarter trial design. The article at the center of today's episode is: "Evaluating eligibility criteria of oncology trials using real-world data and AI" by Ruishan Liu, Shemra Rizzo, Samuel Whipple, Navdeep Pal, Arturo Lopez Pineda, Michael Lu, Brandon Arnieri, Ying Lu, William Capra, Ryan Copping & James Zou, published in Nature.

Biomedical data scientist Sylvia Plevritis is an expert in computational modeling of cancer risk and treatment options hidden in the remarkable quantity of data available today. Rarely is a tumor made up of a single mutation, she says, but more commonly of a mix of different mutations. Such heterogenous tumors may require complex combinations of drugs to produce the most effective treatments. That's where computers can help. Using mathematical simulations, Plevritis is helping patients and their doctors understand the genetic makeup of a given cancer for the purpose of identifying drug combinations that stand a better chance of success. Some of the models Plevritis works with can be run in an hour or less and yet return invaluable guidance that can save a patient's life. Plevritis says these computational approaches can even help those without cancer understand their inherent genetic risks to assess whether and when additional screening or risk-reducing interventions are warranted. Join host Russ Altman and biomedical data scientist Sylvia Plevritis as they dive into the promising intersection of computers and cancer care. You can listen to The Future of Everything on Sirius XM Insight Channel 121, iTunes, Google Play, SoundCloud, Spotify, Stitcher or via Stanford Engineering Magazine.

Imagine an all-encompassing platform that allows you to keep track of all your blood, stool, saliva, and urine testing results, along with self-quantified data from wearables, and even pulls in all health testing you've done in the past as part of a single dashboard. And imagine that platform could then use highly advanced artificial intelligence to tell you exactly how to eat, how to supplement, how to exercise and much more. All from the comfort of your home, without needing to drive to an expensive lab for multiple blood draws or fill out confusing paperwork. That's exactly what the brand new company has the money, technology and data to do, and so I decided it was high time I sat down with their two chief scientists to learn exactly how this process works. I've already sent in my own stool using their Gut/bio shotgun stool sequencing test that we discuss in this episode. My guests are Dr. Joel Dudley and Dr. Chris Mason.  These guys are highly qualified and wicked smart. Dr. Dudley is currently Associate Professor of Genetics and Genomic Sciences, Endowed Chair of Biomedical Data Science, and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine. His work, published in >120 peer-review publications, is focused at the nexus digital health, artificial intelligence (AI), scientific wellness, and healthcare delivery. His work has been featured in the Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. He was named in 2014 as one of the 100 most creative people in business by Fast Company magazine. He is co-author of the book Exploring Personal Genomics from Oxford University Press. Dr. Dudley received a BS in Microbiology from Arizona State University and an MS and PhD in Biomedical Informatics from Stanford University School of Medicine. Dr. Christopher Mason is currently an Associate Professor at Weill Cornell Medicine, with appointments at the Tri-Institutional Program in Computational Biology and Medicine between Cornell, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine, the Sandra and Edward Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute. He is also Director of the WorldQuant Initiative for Quantitative Prediction, which bridges prediction methods in finance with genomics. His work spanning >140 peer-reviewed publications has been featured on the cover of Science, Nature, and Cell journals as well as the New York Times, Wall Street Journal, CNN, Forbes, and other major media outlets. Dr. Mason was featured as a speaker at TEDMED and he was recognized in 2014 as one of the “Brilliant Ten” by Popular Science magazine. He completed his dual B.S. in Genetics and Biochemistry (2001) from University of Wisconsin-Madison, his Ph.D. in Genetics (2006) from Yale University, and then completed post-doctoral training in clinical genetics (2009) at Yale Medical School while jointly a post-doctoral Fellow of Genomics, Ethics, and Law at Yale Law School (2009). During the show, you'll discover: -What is, and what it does...9:45 "Health intelligence" company History of the company Frustration with how long it takes research to reach the consumer 17 years to reach just the clinic; many years after that to reach the consumer How is it different from other biome testing companies Shotgun sequencing vs. 16S Translate the results along with actionable steps to take Recreational health information vs. health management companies Vertically integrated with Thorne, who develops the actual solutions Starting over in some ways in the realm of microbiome testing -What is metatranscriptome analysis?...18:00 "Meta" = Across all species DNA + RNA analysis Challenges with RNA analysis - some clinicians consider it useless Only top few % of species generate RNA in the sample Comparable in price to shotgun sequencing -The actual testing process at Onegevity...20:45 Very small stool sample required, as compared to other tests 6 gigabytes of data after sequencing DNA Each fragment compared to all known species on earth Interactive report on the web; suggestions on what food and supplements to order Network modeling: How are changes in the microbiome propagating to the blood More comprehensive than guessing based on correlations What is measured in the blood? TBD based on the individual's health -How Joel and Chris overcome challenges and skepticism in their testing processes...28:20 How can you measure the whole gut with a stool sample? (Spatial microbiome testing) Not necessary, even harmful, to sample from other areas of the gut -The role of artificial intelligence (AI) in the testing process at Onegevity...36:40 Predicts diseases/conditions based on the shotgun sequencing Recommend foods and supplements to consume Each company has its own variables, testing protocols, etc.; results in differing test results Database continues to grow with each test; data becomes more reliable Data is not for sale to outside parties; will partner under the right conditions -How do you go from stool, to shotgun sequencing, to "don't eat green beans?"...40:35 Internal trial; shocking results Can determine the efficacy of the test at certain benchmarks; 15 day, 30 day, etc. Very positive feedback from those who were tested Does Thorne produce a special probiotic that seeds the gut? -How comprehensive are the dietary recommendations after a Onegevity test?...48:52 Not simply a particular diet, i.e. Mediterranean, Ketogenic, etc. Can make specific food, meal recommendations Possibly partner with food delivery services to provide customized options Very close to being perfectly genetically tailored in both microbiome and saliva tests -How customer data is protected if Joel and Chris choose to partner with a pharmaceutical company...55:20 Customers are opted out by default; can choose to opt in. Potential to benefit monetarily by opting in -What the Onegevity platform looks like from a user standpoint...1:01:55 -And much more! Resources from this episode: - Use discount code BEN20 to receive $20 off your own test. -Book: Exploring Personal Genomics by Joel Dudley Episode Sponsors: - My own company where I develop coffees, energy bars and supplements. I'm also proud to endorse the Thorne line of supplements, including the multi-vitamin, which I take every day. - Wake up each day feeling rested. Relax your body after a long day. Help stiff joints feel young again. Use discount code “greenfield” and get 20% off your entire order! - Your Favorite Organic Foods and Products. Up to 50% Off. Delivered to Your Door. Use my link and get an extra 25% off your first order. - Gently push your body into Ketosis in a healthy manner so your body turns into a fat-burning machine (and stays in fat-burning mode). Get 15% off your order when you use my link. Do you have questions, thoughts or feedback for Joel, Chris or me? Leave your comments at http://bengreenfieldfitness.com/onegevity and one of us will reply!

Brad Efron is Max H. Stein Professor of Humanities and Sciences and Professor of Statistics at Stanford University, and Professor of Biostatistics with the Department of Biomedical Data Science in the Stanford School of Medicine; he serves as Co-director of the undergraduate Mathematical and Computational Sciences Program administered by the Department of Statistics. He has held visiting faculty appointments at Harvard, UC Berkeley, and Imperial College, London. He has been recognized with the 2018 International Prize in Statistics.

Norris Cotton Cancer Center Grand Rounds presented on October 30, 2018 Alfredo Tirado-Ramos, PhD, MSC Associate Professor of Biomedical Data Science and Professor of Epidemiology William Haslett, PhD Research Scientist, Biomedical Informatics John Higgins, MS Data Scientist, Biomedical Informatic

Artificial Intelligence is the next frontier in Healthcare. This Week we speak with Anthony Chang, Medical Director of CHOC Heart Failure Program and founder and Chief Intelligence Officer for the Sharon Disney Lund Medical Intelligence and Innovation Institute (MI3) and an M.S. in Biomedical Data Science with subspecialization from the Stanford School of Medicine. Wonderful conversation on the future of healthcare and medicine.

This week we explore the topic of Artificial Intelligence with a true expert in the field, Dr. Anthony Chang who is chief intelligence and innovation officer at Children's Hospital of Orange County. Dr. Chang recently earned a master’s degree in Biomedical Data Science and Artificial Intelligence from Stanford University and he reviews with us what AI is, what the potential value of this technology might be for medicine and discusses the obstacles that exist for full implementation and development for medical applications. Should we embrace or be fearful of this future? Dr. Chang will provide the answers….

This week we explore the topic of Artificial Intelligence with a true expert in the field, Dr. Anthony Chang who is chief intelligence and innovation officer at Children's Hospital of Orange County. Dr. Chang recently earned a master’s degree in Biomedical Data Science and Artificial Intelligence from Stanford University and he reviews with us what AI is, what the potential value of this technology might be for medicine and discusses the obstacles that exist for full implementation and development for medical applications. Should we embrace or be fearful of this future? Dr. Chang will provide the answers….

Dr. Carlos Bustamante, Professor of Biomedical Data Science and Genetics at Stanford and MacArthur “Genius” Fellow, shares his insights on population genetics and analyzing genome-wide patterns of variation to address fundamental questions in biology, anthropology, and medicine.

At the SAP Healthcare Personalized Medicine Symposium in Palo Alto California, Gregg Masters, MPH chats with Professor of Biomedical Data Science and Genetics, Carlos Bustamante, PhD. For more information see: Bustamante Lab.Faculty included: Bill McDermott – SAP CEOCarlos D. Bustamante, MD & PhD – Professor of Genetics, Inaugural Chair of the Biomedical Science Department, Stanford University School of MedicineDr. David Delaney – SAP’s Chief Medical OfficerEuan Ashley – Associate Professor of Medicine and Genetics, and by courtesy, Pathology & Director, Stanford Clinical Genomics ServiceMagnus Peterson, MD & PhD – Specialist in General Medicine and Pain Rehabilitation; Department of Public Health and Caring Sciences, Uppsala University; Coordinator of Academic Primary Care, Norrtälje TioHundra AB, Karolinska InstituteDr. Peter Paul Yu, MD – FACP, FASCO Immediate Past President, American Society of Clinical Oncology